Respiratory Syncytial Virus hospitalizations burden: a nation-wide population-based analysis, 2000-2017

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract morbidity, particularly among young infants and children1. It can also cause lower respiratory tract morbidity in elderly individuals, particularly in patients with chronic pulmonary and cardiac diseases or immunodeficiency2. Presently, the only available modality for preventing illness due to RSV consists of passive immunization with a humanized monoclonal antibody (Palivizumab) directed towards the RSV F protein3. However, it is restricted to specific high-risk infants and children4, and requires substantial financial resources5.
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research